Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
Eli Lilly and Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for LLY.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). LLY Stock Intelligence Report. [stoxpulse.com/stocks/lly]
Disclaimer: The information on this page about Eli Lilly and Company (LLY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Eli Lilly and Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 27%
Mar 31
Sulzberger bought 5.018 shares
May 18
LUCIANO bought 16.109 shares
May 18
UnitedHealth, Eli Lilly Lead Healthcare Rebound as...
3h ago
Novo And Lilly Push Beyond US As Only 1%-2% Use Ob...
3h ago
StoxPulse AI results for LLY: Pulse Score 51/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$1.08T
P/E Ratio
46.8
EPS
$7.39
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+14.5%
Sep 25
+22.0%
Dec 25
+11.9%
Mar 26
+27.0%
Beat estimates 4 of 4 quarters (100%)
Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
UnitedHealth, Eli Lilly Lead Healthcare Rebound as Investors Seek Stability
Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
GLP-1 Sales Forecast Jumps To $150 Billion By 2030
Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Jim Cramer Details How Eli Lilly Could Defeat Competitors
10 Health Care Stocks Whale Activity In Today's Session